Search
Displaying 1–10 of 471 results
-
Gold Partner and Accessibility Underwriter - Spark Therapeutics
Gold Partner & Accessibility Underwriter Spark Therapeutics
-
Vision Webinar Videos - Spring 2020
Videos recorded during the Foundation Fighting Blindness Vision Webinars held 3/28 - 4/25, 2020
-
Biogen Entering into Licensing Agreement with Mass Eye and Ear to Develop PRPF31 Gene Therapy
The goal of the partnership is to advance a PRPF31 gene therapy into a clinical trial
-
Translational Research Acceleration Program (TRAP) Award
The Translational Research Acceleration Program (TRAP) awards will accelerate the movement of preclinical research toward an Investigational New Drug filing and into clinical trials to provide a robust and diverse pipeline of potential therapies to fight inherited retinal degenerations (IRD) and dry age-related macular degeneration.
-
Tracy was the fourth generation of his family to receive the diagnosis of retinitis pigmentosa, but he never let that stop him from dreaming big. Tracy has worked at NASA’s Johnson Space Center for over 36 years, making significant contributions over the many years.
-
Refsum disease is an inherited condition that causes vision loss, absence of the sense of smell, and a number of other symptoms.
-
Release Date: June 5, 2020 Expiration Date: May 29, 2023
This activity offers CE credit for: a. Physicians (CME) b. Optometrists (COPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™.
-
Virtual VISIONS 2020 Recorded Sessions
Recorded presentations from Virtual Visions 2020.
-
Bionic Sight Doses First Patient in Clinical Trial for Optogenetic Therapy
Treatment combines gene therapy and a device that generates and delivers retinal code
-
Foundation Fighting Blindness to Host Virtual VISIONS 2020 Conference
The national conference will be held virtually on June 25-27, providing the latest in science and research, practical adapting and thriving, and an opportunity to connect with others who are visually impaired.
